home / stock / avir / avir articles

AVIR Articles, Atea Pharmaceuticals Inc.

Stock Information
Company Name: Atea Pharmaceuticals Inc.
Stock Symbol: AVIR
Market: NASDAQ
Website: ateapharma.com
Menu
AVIR AVIR Quote AVIR Short AVIR News AVIR Articles AVIR Message Board
Get AVIR Alerts

News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus | Benzinga

Atea Pharmaceuticals Inc (NASDAQ:AVIR) announced Wednesday new data from the lead-in cohort (n=60) of the company’s ongoing Phase 2 combinati...
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 | Benzinga

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highligh...

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024 | Benzinga

BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea), a clinical-stage biopharmaceutical company engaged i...

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024 | Benzinga

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged ...
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy | Benzinga

Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eigh...

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Benzinga

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged ...

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 | Benzinga

First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study Plasma Pharmacokinet...
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences | Benzinga

BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged ...

Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023 | Benzinga

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company ...

Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023 | Benzinga

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged ...
Next 10